Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood RI Kresladi Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Kresladi (marnetegragene autotemcel) (Intravenous)

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of one intravenous treatment course of Kresladi for eligible pediatric members with severe leukocyte adhesion deficiency type I (LAD-I). It applies to Medicaid, Commercial, and Medicare members.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyKresladi (marnetegragene autotemcel) (Intravenous)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Last ReviewAug 18, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation establishing medical necessity and demonstrating that all initial coverage criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 doseMaximum treatment course
    ≥3 monthsMinimum age
    D71.1Covered diagnosis
    2.8 × 10^6/kgRecommended minimum dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial therapy for severe LAD-I

    Covered when ALL of the following are met.

    Initial Kresladi coverage

    • Age and diagnosis

      • Disease-expression threshold: Neutrophil CD18 expression is below 2%, or CD11a and/or CD11b expression is below 2% when neutrophil CD18 expression is at least 2%.CD18 <2%; or CD11a and/or CD11b <2% if CD18 ≥2%
      • Molecular and clinical confirmation: Member has documented biallelic ITGB2 mutations and a clinical history consistent with severe LAD-I or a known family history.Biallelic ITGB2 mutations
      • Prior infection: Member has at least one prior significant, medically documented bacterial or fungal infection.≥1 infection
    • Transplant and donor requirements: Member is a candidate for autologous HSCT, has not had prior HSCT, and does not have a known and available suitable 10/10 HLA-matched related donor willing to participate in allogeneic HSCT.No prior HSCT; no available suitable 10/10 HLA-matched related donor
    • Mobilization and safety requirements: Member will undergo mobilization with G-CSF and plerixafor before apheresis; has no active or clinically significant systemic infection; will be monitored for infection before and after infusion with prophylactic antimicrobials per institutional guidelines; and will be monitored for veno-occlusive disease with liver function testing during the first month after infusion.
    • HIV and antiretroviral requirements: Member has screened negative for HIV according to clinical guidelines before mobilization and apheresis and will not receive prophylactic HIV ART. If prophylactic ART is being used, it must be stopped for at least one month before mobilization or for the duration required to eliminate the medications, and until all apheresis cycles are complete.Negative pre-treatment HIV screening; no prophylactic ART

      Post-treatment PCR-based HIV testing may be falsely positive because of LVV provirus insertion.

    • Post-treatment monitoring and administration requirements: Member will be monitored for LVV-mediated insertional oncogenic hematologic malignancies, monitored and managed for severe DMSO hypersensitivity during and after infusion, treated at an Authorized Treatment Center, and will not have received prior gene therapy for LAD-I including Kresladi.One-time treatment at an ATC

      Retreatment is considered investigational and is reviewed case by case.

    Prior gene therapy for LAD-I, including Kresladi (marnetegragene autotemcel), excludes routine coverage under these criteria. Retreatment requests may be considered only through case-by-case review based on the totality of the clinical circumstances and supporting documentation.

    Coverage under these criteria is excluded when the member has a known and available suitable 10/10 HLA-matched related donor who is willing to participate in allogeneic HSCT.

    The member must have no active or clinically significant systemic infection at the time of treatment. Treatment is excluded until the infection or condition has been addressed.

    Repeat administration or retreatment with marnetegragene autotemcel is considered investigational because available evidence is insufficient to establish the safety and effectiveness of repeat administration.

    Coding and Clinical Limits

    HCPCS Code(s)HCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals (Hospital Outpatient Use Only)
    NDCNDC
    835370034-xxKresladi 50 mL infusion bag and metal cassette; supplied in one or two infusion bags containing a frozen suspension of genetically modified autologous cells enriched for CD34+ cells
    Covered Diagnosis CodesICD-10Covered
    D71.1Leukocyte adhesion deficiency
    Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/Amixed
    No codes listed
    Maximum Dose
    Maximum dose1 dose up to 3.22 × 10^8 CD34+ cells
    Treatment courseCoverage is limited to one treatment course consisting of 1 dose of Kresladi
    RenewalThe treatment course may not be renewed
    Minimum Age
    Minimum ageMember must be ≥3 months of age
    Covered conditionConfirmed severe leukocyte adhesion deficiency type I (LAD-I)
    Diagnostic confirmationDiagnosis must be established by a specialist provider, such as a hematologist/oncologist, immunologist, geneticist, or infectious disease specialist
    Neutrophil CD18 Expression
    CD18 expressionNeutrophil CD18 expression <2%
    CD11a expressionCD11a expression <2% when neutrophil CD18 expression is ≥2%
    CD11b expressionCD11b expression <2% when neutrophil CD18 expression is ≥2%
    Recommended Minimum Dose
    Recommended minimum dose2.8 × 10^6 CD34+ cells/kg
    AdministrationSingle intravenous infusion
    UseFor autologous use only and one-time single-dose intravenous use only

    Authorization and Provider Requirements

    Prior Authorization

    Prior Authorization and Initial Criteria

    Prior authorization is required for Kresladi. Submit documentation establishing medical necessity and demonstrating that all applicable initial coverage criteria are satisfied.

    • Requests must include supporting clinical documentation related to the diagnosis, clinical markers, treatment planning, and other applicable initial criteria.
    Step Therapy

    Medicare Prior-Treatment Exception

    Medicare members who received Kresladi within the preceding 365 days are not subject to the policy’s step therapy requirements.

    • The prior-treatment exception applies only to Medicare members with documented Kresladi treatment during the past 365 days.
    Note

    Individual Coverage Determination

    Neighborhood will give individual consideration to each request based on information submitted by the prescriber and other information available to the plan. Coverage criteria apply to Medicare members only when NCD or LCD criteria are absent.

    Documentation Required

    Required Clinical Documentation

    Submit supporting clinical documentation with every authorization request, including medical records, chart notes, laboratory results, confirmatory diagnostics, diagnosis, step-therapy history, and clinical markers such as genetic or mutational testing when applicable.

    • Provide records by direct upload through the prior authorization web portal or by fax.
    • Documentation must support the medical necessity criteria and initiation of treatment.
    Documentation Required

    LAD-I Eligibility and Treatment Planning Records

    For LAD-I coverage, submit records establishing the member’s eligibility and treatment plan. The records must support all applicable diagnostic, clinical, transplant-candidacy, infection-monitoring, and Authorized Treatment Center requirements.

    • Member is at least 3 months of age.
    • A specialist provider—such as a hematologist/oncologist, immunologist, geneticist, or infectious disease specialist—has confirmed severe LAD-I.
    • Neutrophil CD18 expression is <2%, or CD11a and/or CD11b expression is <2% when neutrophil CD18 expression is ≥2%.
    • Biallelic ITGB2 mutations are documented.
    • The clinical history is consistent with severe LAD-I or there is a known family history.
    • The member has at least one prior significant, medically documented bacterial or fungal infection.
    • The member is a candidate for autologous hematopoietic stem cell transplant (HSCT), has not had prior HSCT, and does not have a known and available suitable 10/10 HLA-matched related donor willing to participate in allogeneic HSCT.
    • The member will undergo mobilization with G-CSF and plerixafor before apheresis.
    • The member has no active or clinically significant systemic infection, will be monitored for infection before and after infusion, and will receive prophylactic antimicrobials according to institutional guidelines.
    • The member will be monitored for veno-occlusive disease, including liver function testing during the first month after infusion.
    • The member has screened negative for HIV according to clinical guidelines before mobilization and apheresis. HIV screening should not use a PCR-based assay after Kresladi because lentiviral-vector provirus insertion may cause a false-positive PCR result.
    Note

    Submit Clinical Information for Individual Review

    Prescribers must submit the clinical information needed for individual review. Neighborhood evaluates each request using the prescriber-submitted information together with other information available to the plan.

    • Include all records necessary to evaluate diagnosis, medical necessity, clinical eligibility, treatment planning, and applicable coverage criteria.
    Denial Risk

    Insufficient Supporting Documentation

    A request may be denied when required medical records or supporting documentation are not submitted, because the plan cannot establish medical necessity in accordance with the policy.

    • Missing chart notes, laboratory results, confirmatory diagnostics, genetic or mutational testing, diagnosis, step-therapy information, or other required treatment records may result in denial.
    Denial Risk

    Failure to Meet Clinical Eligibility Criteria

    A request may be denied when the member does not meet the applicable diagnostic, clinical, transplant-candidacy, treatment-planning, monitoring, or other LAD-I eligibility criteria.

    • All applicable initial criteria must be supported by submitted documentation.
    Denial Risk

    Retreatment Is Investigational

    Retreatment with marnetegragene autotemcel is considered investigational and is not covered as established medically necessary therapy. Although limited retreatment was reported for one patient in the pivotal study, available evidence is insufficient to establish the safety and effectiveness of repeat administration.

    • Retreatment requests may be reviewed case by case based on the totality of the clinical circumstances and supporting documentation.
    Billing Rule

    Nonrenewable One-Time Treatment

    Coverage is limited to one treatment course consisting of one dose of Kresladi and cannot be renewed.

    • A renewal request is not covered.
    • The member must not have received prior gene therapy for LAD-I, including Kresladi, except that any retreatment request is investigational and subject to case-by-case review.
    Billing Rule

    Applicable Medicare Coverage Criteria

    For Medicare coverage determinations, follow applicable CMS requirements for outpatient Part B drugs, including the Medicare Benefit Policy Manual (Publication 100-2), Chapter 15, §50, and any applicable National Coverage Determination (NCD), Local Coverage Determination (LCD), or Local Coverage Article (LCA).

    • The preceding Neighborhood criteria are intended for non-Medicare coverage determinations.
    • NCD and LCD requirements must be followed where applicable; LCAs may affect claims payment or clarify Part B benefit eligibility.
    • CMS coverage documents may be searched at https://www.cms.gov/medicare-coverage-database/search.aspx.

    Therapy Background

    Kresladi (marnetegragene autotemcel) is an autologous hematopoietic stem cell-based gene therapy for pediatric patients with severe leukocyte adhesion deficiency type I (LAD-I) caused by biallelic ITGB2 variants. It is administered as a single intravenous treatment for eligible patients who are candidates for autologous HSCT and do not have an available suitable 10/10 HLA-matched related donor for allogeneic HSCT.

    Definitions

    Severe Leukocyte Adhesion Deficiency Type I
    Neutrophil expressionCD18 expression <2%, or CD11a and/or CD11b expression <2% if CD18 expression is ≥2%
    Molecular confirmationDocumented biallelic ITGB2 mutations
    Clinical or family historyClinical history consistent with severe LAD-I or a known family history
    Prior infectionAt least 1 prior significant, medically documented bacterial or fungal infection
    Authorized Treatment Center
    DefinitionDesignated treatment facility for Kresladi administration and associated transplant-related care
    Treatment requirementKresladi treatment must occur at an Authorized Treatment Center
    Associated careThe center provides the setting for treatment-related monitoring and care connected with autologous hematopoietic stem cell transplantation

    Initial Therapy

    Initial therapy for severe LAD-I

    Initial treatment is covered only when all policy criteria are satisfied.

    Kresladi initial therapy

    • Age and diagnosis

      • Disease-expression threshold: Neutrophil CD18 expression is below 2%, or CD11a and/or CD11b expression is below 2% when neutrophil CD18 expression is at least 2%.CD18 <2%; or CD11a and/or CD11b <2% if CD18 ≥2%
      • Molecular and clinical confirmation: Member has documented biallelic ITGB2 mutations and a clinical history consistent with severe LAD-I or a known family history.Biallelic ITGB2 mutations
      • Prior infection: Member has at least one prior significant, medically documented bacterial or fungal infection.≥1 infection
    • Transplant and donor requirements: Member is a candidate for autologous HSCT, has not had prior HSCT, and does not have a known and available suitable 10/10 HLA-matched related donor willing to participate in allogeneic HSCT.No prior HSCT; no available suitable 10/10 HLA-matched related donor
    • Mobilization and safety requirements: Member will undergo mobilization with G-CSF and plerixafor before apheresis; has no active or clinically significant systemic infection; will be monitored for infection before and after infusion with prophylactic antimicrobials per institutional guidelines; and will be monitored for veno-occlusive disease with liver function testing during the first month after infusion.
    • HIV and antiretroviral requirements: Member has screened negative for HIV according to clinical guidelines before mobilization and apheresis and will not receive prophylactic HIV ART. If prophylactic ART is being used, it must be stopped for at least one month before mobilization or for the duration required to eliminate the medications, and until all apheresis cycles are complete.Negative pre-treatment HIV screening; no prophylactic ART

      Post-treatment PCR-based HIV testing may be falsely positive because of LVV provirus insertion.

    • Post-treatment monitoring and administration requirements: Member will be monitored for LVV-mediated insertional oncogenic hematologic malignancies, monitored and managed for severe DMSO hypersensitivity during and after infusion, treated at an Authorized Treatment Center, and will not have received prior gene therapy for LAD-I including Kresladi.One-time treatment at an ATC

      Retreatment is considered investigational and is reviewed case by case.

    Continuation and Renewal

    No continuation therapy

    Continuation or renewal is not available.

    No renewal: Coverage is limited to one treatment course consisting of one dose of Kresladi and cannot be renewed.1 treatment course; 1 dose

    Step Therapy

    StepMember populationStep therapy requirement
    1Medicare members who have previously received Kresladi within the past 365 daysNot subject to step therapy requirements

    Quantity Limits

    Kresladi Quantity Limit
    Quantity limit1 dose per treatment course
    Cell limitUp to 3.22 × 10^8 CD34+ cells per dose
    Time limitUp to 3.22 × 10^8 CD34+ cells over time
    RenewalCoverage is limited to one treatment course and may not be renewed

    Site of Care

    Billing Rule

    Use an Authorized Treatment Center

    Administer Kresladi at an Authorized Treatment Center. The policy specifies the Authorized Treatment Center as the required treatment site for this hospital outpatient therapy.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyKresladi (marnetegragene autotemcel) (Intravenous)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Last ReviewAug 18, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation establishing medical necessity and demonstrating that all initial coverage criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical LimitsAuthorization and Provider RequirementsTherapy BackgroundDefinitionsInitial TherapyContinuation and RenewalStep TherapyQuantity LimitsSite of Care
  1. The member will not receive prophylactic HIV antiretroviral therapy; any such therapy must be stopped for at least one month before mobilization, or for the expected time required for elimination, and until all apheresis cycles are complete.
  2. The member will be monitored for lentiviral-vector-mediated insertional oncogenic hematologic malignancies as clinically indicated.
  3. The member will be monitored and managed according to clinical practice for severe DMSO hypersensitivity during and after infusion.
  4. Treatment will occur at an Authorized Treatment Center (ATC).
  5. The member has not received prior gene therapy for LAD-I, including Kresladi.